跳至內容

泊馬度胺

維基百科,自由的百科全書
泊馬度胺
臨床資料
商品名英語Drug nomenclaturePomalyst, Imnovid
AHFS/Drugs.comMonograph
MedlinePlusa613030
核准狀況
懷孕分級
  • : X (高風險) [1]
給藥途徑By mouth
ATC碼
法律規範狀態
法律規範
藥物動力學數據
生物利用度73% (at least)[8]
血漿蛋白結合率12–44%
藥物代謝Liver (mostly CYP1A2- and CYP3A4-mediated; some minor contributions by CYP2C19 and CYP2D6)
生物半衰期7.5 hours
排泄途徑Urine (73%), faeces (15%)
識別資訊
  • 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
CAS號19171-19-8  checkY
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard英語CompTox Chemicals Dashboard (EPA)
ECHA InfoCard100.232.884 編輯維基數據鏈接
化學資訊
化學式C13H11N3O4
摩爾質量273.25 g·mol−1
3D模型(JSmol英語JSmol
手性Racemic mixture
  • C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N
  • InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18) ☒N
  • Key:UVSMNLNDYGZFPF-UHFFFAOYSA-N ☒N

泊馬度胺(英語:Pomalidomide,商品名有PomalystImnovid)是一種含氮有機化合物,化學式為C13H11N3O4,可作為化療藥物[7],用於治療多發性骨髓瘤AIDS相關的卡波西肉瘤[6]

參考文獻

  1. ^ Pomalidomide (Pomalyst) Use During Pregnancy. Drugs.com. 14 May 2020 [21 September 2020]. (原始內容存檔於25 January 2021). 
  2. ^ Pomalidomide Medicianz/ Pomalimed/ Pomalidomide Medsurge (Medicianz Healthcare Pty Ltd). Therapeutic Goods Administration (TGA). 5 December 2022 [9 April 2023]. (原始內容存檔於18 March 2023). 
  3. ^ Prescription medicines: registration of new chemical entities in Australia, 2014. Therapeutic Goods Administration (TGA). 21 June 2022 [10 April 2023]. (原始內容存檔於10 April 2023). 
  4. ^ Product information. 
  5. ^ Imnovid 1 mg hard capsules - Summary of Product Characteristics (SmPC). (emc). 16 June 2020 [21 September 2020]. (原始內容存檔於26 October 2020). 
  6. ^ 6.0 6.1 Pomalyst- pomalidomide capsule. DailyMed. 7 December 2017 [21 September 2020]. (原始內容存檔於20 October 2020). 
  7. ^ 7.0 7.1 Imnovid EPAR. European Medicines Agency (EMA). 17 September 2018 [21 September 2020]. (原始內容存檔於27 October 2020).  Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  8. ^ Imnovid 1 mg Hard Capsules. Summary of Product Characteristics. 5.2 Pharmacokinetic properties (PDF). Celgene Europe Ltd.: 22. [21 August 2016]. (原始內容存檔 (PDF)於27 June 2016). 
  9. ^ Anvisa. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control]. Diário Oficial da União. 2023-03-31 (2023-04-04) [2023-08-15]. (原始內容存檔於2023-08-03) (巴西葡萄牙語).